Training cohort | Validation cohort | |||||
---|---|---|---|---|---|---|
Clinicopathological parameters/biomarker | n | Hazard ratio (95 % CI) | p value | n | Hazard ratio (95 % CI) | p value |
Age | 411 | 1.02 (0.98–1.06) | 0.39 | 259 | 1.01 (0.96–1.06) | 0.70 |
Tumor stage (pT3 and pT4 vs. pT2 and pT1) | 346 | 4.25 (2.37–7.61) | <0.001 | 260 | 2.07 (1.30–3.30) | 0.001 |
ISUP Gleason grading group | 411 | 1.69 (1.34–2.13) | <0.001 | 252 | 1.99 (1.63–2.42) | <0.001 |
Surgical margin (R1 vs. R0) | 389 | 1.49 (0.87–2.56) | 0.15 | 258 | 1.00 (0.98–1.02) | 0.84 |
Nodal status (pN1 vs. pN0) | 357 | 1.84 (1.00–3.36) | 0.048 | 259 | 1.09 (0.50–2.41) | 0.82 |
Preoperative PSA level | 409 | 1.04 (1.02–1.05) | <0.001 | 250 | 1.01 (1.00–1.02) | 0.11 |
AR activity score (positive vs. negative) | 271 | 0.74 (0.32–1.71) | 0.49 | NA | NA | NA |
AR protein expression (AR high vs. AR low) | NA | NA | NA | 143 | 0.82 (0.40–1.70) | 0.60 |
ERGa (ERG-fusion positive vs. ERG-fusion negative) | 271 | 0.80 (0.40–1.57) | 0.51 | 182 | 0.78 (0.40–1.51) | 0.46 |
mPITX3 (optimized cutoff, mPITX3 high vs. mPITX3 low) | 411 | 1.83 (1.07–3.11) | 0.027 | 250 | 2.56 (1.44–4.54) | 0.001 |